Trial Profile
An Open-Label, Phase Ia/Ib/IIa Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jan 2023
Price :
$35
*
At a glance
- Drugs Brilanestrant (Primary) ; LHRH receptor agonists; Palbociclib
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Genentech; Seragon Pharmaceuticals
- 01 Jan 2023 Results assessing safety, pharmacokinetics, and recommended phase 2 dose (RP2D) of GDC-0810 in postmenopausal women with ER + (HER2 -) locally advanced or metastatic breast cancer published in the Breast Cancer Research and Treatment
- 09 Nov 2020 This trial has been completed in Netherlands according to European Clinical Trials Database record.
- 19 Mar 2020 Status changed from active, no longer recruiting to discontinued.